Name in SEC filings: Moderna, Inc.
Source: ORION, orionbiotechai.com/company/MRNA, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/MRNA
intismeran autogene · Topline/data readout · 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout2026
Stage: Phase 3SEC filing · “Phase 3”
Public float: $9,900,000,000 · as of · SEC filing
Phase 3 adjuvant melanoma data potentially in 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2026
Stage: Not stated
Public float: $9,900,000,000 · as of · SEC filing
data expected in 2026, subject to case accruals
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2026
Stage: Not stated
Public float: $9,900,000,000 · as of · SEC filing
We expect potential data in 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $9,900,000,000 · as of · SEC filing
we expect a potential Phase 2 data readout in 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| mRNA-3927Clinical results | 2026“We expect potential data in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| mRNA-1403Clinical results | 2026“data expected in 2026, subject to case accruals” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| mRNA-3927Clinical results | 2026“data expected in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| mRNA-4359Clinical results | 2026“we expect a potential Phase 2 data readout in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| mRNA-4359Clinical results | 2026“Phase 2 data readout in 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| intismeran autogeneClinical results | 2026“Phase 3 adjuvant melanoma data potentially in 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| mRNA-4359Clinical results | 2026“Phase 2 data readout in 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| mRNA-4359Clinical results | 2026“Phase 2 data readout in 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
We expect Phase 3 adjuvant melanoma data potentially in 2026.
We expect potential data in 2026.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for MRNA. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See MRNA in the calendar · Review labels and methodology